[go: up one dir, main page]

IL115766A0 - Composition and treatment for multiple sclerosis - Google Patents

Composition and treatment for multiple sclerosis

Info

Publication number
IL115766A0
IL115766A0 IL11576695A IL11576695A IL115766A0 IL 115766 A0 IL115766 A0 IL 115766A0 IL 11576695 A IL11576695 A IL 11576695A IL 11576695 A IL11576695 A IL 11576695A IL 115766 A0 IL115766 A0 IL 115766A0
Authority
IL
Israel
Prior art keywords
treatment
composition
multiple sclerosis
sclerosis
Prior art date
Application number
IL11576695A
Other languages
English (en)
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of IL115766A0 publication Critical patent/IL115766A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL11576695A 1994-10-25 1995-10-25 Composition and treatment for multiple sclerosis IL115766A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15

Publications (1)

Publication Number Publication Date
IL115766A0 true IL115766A0 (en) 1996-01-19

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11576695A IL115766A0 (en) 1994-10-25 1995-10-25 Composition and treatment for multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (fr)
JP (1) JPH10504039A (fr)
AU (1) AU4278296A (fr)
BR (1) BR9509438A (fr)
CA (1) CA2203629A1 (fr)
CZ (1) CZ122697A3 (fr)
FI (1) FI971750A7 (fr)
HU (1) HUT77047A (fr)
IL (1) IL115766A0 (fr)
IS (1) IS4466A (fr)
NO (1) NO971900L (fr)
PL (1) PL324091A1 (fr)
SI (1) SI9520118A (fr)
SK (1) SK51297A3 (fr)
WO (1) WO1996012737A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
GB2349463B (en) 1996-03-21 2001-01-10 Circassia Ltd Cryptic peptides and method for their identification
WO1998006861A2 (fr) * 1996-08-15 1998-02-19 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
CA2494338C (fr) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Specificite des peptides de la proteine basique anti-myeline et administration de ces peptides aux patients atteints de sclerose en plaques
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
WO1999057241A2 (fr) * 1998-05-05 1999-11-11 Corixa Corporation Peptides de proteine basique de myeline et utilisations de ceux-ci
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (fr) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation
EP1288226A1 (fr) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification de l'expression des gènes pour les récepteurs type "Toll" destinée à influencer la neurodégénérescence et la neuroprotection de système nerveux central de l'homme
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
MXPA04009361A (es) 2002-03-27 2005-05-17 Aegera Therapeutics Inc Oligomeros de nucleobases iap anti-sentido y sus usos.
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2572734B1 (fr) 2006-10-31 2016-04-06 East Carolina University Protéines de fusion à base de cytokine pour le traitement des troubles immunitaires
WO2010024927A2 (fr) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Traitement des amyloïdoses au moyen de protéines basiques de myéline ou de fragments desdites
CA2757287C (fr) * 2009-03-31 2019-09-10 East Carolina University Cytokines et neuroantigenes utilises dans le traitement de maladies immunitaires
AU2009354040A1 (en) 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (fr) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides presentant une affinite pour les proteines de choc thermique (hsp) et complexes associes a une hsp (hacs) et leur utilisation en diagnostic et en therapie
SG11201605698XA (en) 2014-01-13 2016-08-30 Berg Llc Enolase 1 (eno1) compositions and uses thereof
EP3383892B1 (fr) 2015-12-03 2022-12-21 Juno Therapeutics, Inc. Récepteurs chimériques modifiés et compositions et procédés associés

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (de) * 1987-06-24 2004-02-15 Brigham & Womens Hospital Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
WO1991008760A1 (fr) * 1989-12-20 1991-06-27 Brigham And Women's Hospital Traitement ameliore de maladies auto-immunes par administration par aerosol d'auto-antigenes
ATE157257T1 (de) * 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (fr) * 1991-10-22 2002-03-12 Kenneth G. Warren Specificite pour les peptides synthetiques de la proteine basique anti-myeline presente dans le liquide cephalorachidien de patients atteints de la sclerose en plaques
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
CA2133749A1 (fr) * 1992-04-09 1993-10-28 Howard L. Weiner Suppression de la proliferation de lymphocytes t a l'aide de fragments peptidiques de la proteine de base de la myeline
WO1993025661A1 (fr) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Clones heterogenes de cellules t specifiques contre le peptide proteolipidique 139-151
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
CA2170901A1 (fr) * 1993-09-03 1995-03-09 Brigitte Devaux Utilisations de myeline oligodendrocyte glycoproteine et de fractions peptidiques de ce produit dans des maladies auto-immunes
WO1995007096A1 (fr) * 1993-09-06 1995-03-16 La Trobe University Traitement de maladies auto-immunes
EP0720622A1 (fr) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Interaction des recepteurs de lymphocytes t et de l'antigene dans les maladies auto-immunes
CA2187345A1 (fr) * 1994-04-08 1995-10-19 Howard L. Weiner Traitement de maladies auto-immunes avec des agents d'induction de tolerance et/ou des cytokines de renforcement des th2 administres par voie orale
IL113303A0 (en) * 1994-04-08 1995-07-31 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
WO1995033997A1 (fr) * 1994-06-09 1995-12-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Cristalline alpha b utilisee dans le diagnostic et le traitement de maladies auto-immunes et en particulier la sclerose en plaque
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
EP0792286B1 (fr) * 1994-11-18 2002-02-20 Neurocrine Biosciences, Inc. Analogues peptidiques a la position 91 de la proteine basique de la myeline humaine pour la traitement de la sclerose en plaques

Also Published As

Publication number Publication date
EP0787147A1 (fr) 1997-08-06
HUT77047A (hu) 1998-03-02
WO1996012737A3 (fr) 1996-10-10
JPH10504039A (ja) 1998-04-14
CA2203629A1 (fr) 1996-05-02
CZ122697A3 (en) 1997-09-17
NO971900L (no) 1997-06-25
FI971750A0 (fi) 1997-04-24
IS4466A (is) 1997-04-17
FI971750A7 (fi) 1997-06-24
AU4278296A (en) 1996-05-15
BR9509438A (pt) 1997-12-23
PL324091A1 (en) 1998-05-11
SI9520118A (sl) 1998-08-31
NO971900D0 (no) 1997-04-24
WO1996012737A2 (fr) 1996-05-02
SK51297A3 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
IL115766A0 (en) Composition and treatment for multiple sclerosis
GB9208339D0 (en) Treatment composition
IL115891A0 (en) Hemorrhoidial compositions and their use
ZA952356B (en) Skin treatment composition
GB9415421D0 (en) Cosmetic compositions and processes for manufacture thereof
GB9500856D0 (en) Composition and use
IL113661A0 (en) Compositions and treatment for multiple sclerosis
IL111554A0 (en) Methods and compositions for hair treatment
GB9415420D0 (en) Cosmetic compositions and processes for manufacture thereof
GB9411045D0 (en) Compounds and use
EP0835092A4 (fr) Composition et traitement pour la lutte contre la calvitie
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
ZA952121B (en) Skin treatment composition
GB9415901D0 (en) Novel compounds and treatment
GB9508546D0 (en) Method and composition
GB9415900D0 (en) Novel compounds and treatment
GB9525048D0 (en) Composition compound and use
GB9405046D0 (en) Skin treatment composition
ZA959033B (en) Composition and treatment for multiple sclerosis
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
GB9411349D0 (en) Cleaning composition and cleaning process
GB9416340D0 (en) Oil treatment and compositions therefor
ZA953730B (en) Compositions and treatment for multiple sclerosis
GB9413076D0 (en) Composition and use